---
title: "藥明合聯與 Earendil Labs 達成戰略合作"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/277194774.md"
description: "藥明合聯與 Earendil Labs 達成戰略合作"
datetime: "2026-02-27T12:01:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277194774.md)
  - [en](https://longbridge.com/en/news/277194774.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277194774.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/277194774.md) | [English](https://longbridge.com/en/news/277194774.md)


# 藥明合聯與 Earendil Labs 達成戰略合作



### 相關股票

- [招商中證生物科技主題ETF (159849.CN)](https://longbridge.com/zh-HK/quote/159849.CN.md)
- [華夏醫藥ETF (510660.CN)](https://longbridge.com/zh-HK/quote/510660.CN.md)
- [創新藥 (159992.CN)](https://longbridge.com/zh-HK/quote/159992.CN.md)
- [華夏中證生物科技主題ETF (516500.CN)](https://longbridge.com/zh-HK/quote/516500.CN.md)
- [方正富邦中證醫藥及醫療器械創新ETF (560600.CN)](https://longbridge.com/zh-HK/quote/560600.CN.md)
- [平安中證醫療創新ETF (516820.CN)](https://longbridge.com/zh-HK/quote/516820.CN.md)
- [科創醫藥ETF工銀 (588860.CN)](https://longbridge.com/zh-HK/quote/588860.CN.md)
- [華夏上證科創板生物醫藥ETF (588130.CN)](https://longbridge.com/zh-HK/quote/588130.CN.md)
- [國泰中證生物醫藥ETF (512290.CN)](https://longbridge.com/zh-HK/quote/512290.CN.md)
- [生物科技ETF基金 (516930.CN)](https://longbridge.com/zh-HK/quote/516930.CN.md)
- [藥明合聯 (02268.HK)](https://longbridge.com/zh-HK/quote/02268.HK.md)
- [天弘國證生物醫藥ETF (159859.CN)](https://longbridge.com/zh-HK/quote/159859.CN.md)
- [易方達滬深300醫藥ETF (512010.CN)](https://longbridge.com/zh-HK/quote/512010.CN.md)
- [易方達中證生物科技主題ETF (159837.CN)](https://longbridge.com/zh-HK/quote/159837.CN.md)
- [鵬華上證科創板生物醫藥ETF (588250.CN)](https://longbridge.com/zh-HK/quote/588250.CN.md)

## 相關資訊與研究

- [邦睿營收／去年獲利 1.02 億元 EPS 4.13 元 均同步刷新紀錄](https://longbridge.com/zh-HK/news/277697388.md)
- [【企業盈喜】晶泰控股料全年轉賺不少於 1 億元人民幣](https://longbridge.com/zh-HK/news/277604143.md)
- [高端疫苗總經理李思賢：今年是飛黃騰達的一年 鎖定病毒 71 型疫苗東協市場](https://longbridge.com/zh-HK/news/277594204.md)
- [四環醫藥一款創新藥晚期乳腺癌新適應症獲內地批准上市](https://longbridge.com/zh-HK/news/277591516.md)
- [和譽口服小分子抑制劑標靶藥 ABSK141 完成首例患者給藥](https://longbridge.com/zh-HK/news/277699956.md)